creka peptide can target tumors - creatine-monohydrate-and-collagen-peptides a trifluoroacetic acid form of a short peptide Unveiling the Potential of CREKA Peptide: A Targeted Approach in Biomedical Applications

do-peptides-need-refrigeration The field of targeted drug delivery and diagnostics has seen significant advancements, with peptides emerging as crucial components for enhancing precision and efficacy. Among these, the CREKA peptide has garnered considerable attention due to its unique binding properties and potential applications in various disease areas. This pentapeptide, with the sequence Cys-Arg-Glu-Lys-Ala (CREKA), is a self-assembling peptide that exhibits a remarkable affinity for specific biological targets, making it a desirable component in nanoplatforms and drug delivery systems.

Understanding the CREKA Peptide: Structure and Function

The CREKA peptide is characterized by its self-assembling nature, meaning it can spontaneously form nanostructures.Full article: Targeted drug delivery to the thrombus by ... This property, along with its specific binding capabilities, makes it a valuable tool in biomedical research and development作者：D Zanuy·2009·被引用次数：25—Influence of the dye presence on the conformational preferences ofCREKA, a tumor homing linear pentapeptide. Authors. David Zanuy,.. Unlike fibrin-specific antibodies, the CREKA peptide is considered a less immunogenic, low-cost fibrin-binding peptide.Researchers have found that the peptide CREKAcan target tumors, enable accurate experimental tracking of ultrasmall breast cancer metastases [28], and ... Its high affinity for fibrin, particularly fibrin-fibronectin complexes, which are often overexpressed in pathological conditions, is a key factor driving its applicationCREKA peptide TFA. These complexes are found within the microthrombi associated with various diseases and are also present in the tumor microenvironment, particularly in new tumor vessels during the early stages of metastasis.

Targeted Applications of CREKA Peptide

The precise targeting ability of the CREKA peptide opens doors for a wide range of therapeutic and diagnostic applicationsCREKA peptideis a selective non-covalent binding agent targeting fibrin, type IV collagen, and fibronectin, often used as a targeting ligand to modify .... Research has demonstrated its potential in:

* Cancer Therapy and Imaging: The CREKA peptide has shown promise in targeting tumors, enabling accurate experimental tracking of even ultrasmall metastasesTargeting Cancer Cells via Tumor-homing Peptide CREKA .... CREKA-conjugated nanoparticles have been developed for targeted drug delivery, with studies exploring their effectiveness in inducing apoptosis.Peptide targeted tripod macrocyclic Gd(III) chelates for ... For instance, multifunctional CREKA peptide conjugated lipid nanocarriers have been investigated for synergistic drug delivery in breast cancer. Furthermore, CREKA-modified nanoprobes demonstrate superior site retention and accumulation, facilitating precision imaging applications such as tumor stroma detection. The ability of CREKA to target tumors is a significant advantage in developing more effective cancer treatments.Studies have shown thatCREKA peptidecan effectively target disease areas such as cancer, myocardial ischemia-reperfusion injury and atherosclerosis. Due to ...

* Cardiovascular Diseases: The CREKA peptide can effectively target disease areas such as myocardial ischemia-reperfusion injury and atherosclerosis. Its binding to fibrin makes it valuable for applications related to thrombus detection and treatmentCREKA肽是一种自组装短肽（序列：Cys-Arg-Glu-Lys-Ala），能够特异性识别并结合过度表达的纤维蛋白，靶向治疗癌症、心肌缺血再灌注、动脉粥样硬化等病变，有望应用于纳米医学 .... For example, research has explored the use of the CREKA peptide to develop targeted drug delivery systems for thrombus.

* Other Pathological Conditions: The peptide's affinity for fibrin-fibronectin complexes also positions it for potential use in treating conditions involving lymphovascular invasion formation.作者：Z Zhou·2013·被引用次数：103—CREKA is a tumor-homing pentapeptide(Cys-Arg-Glu-Lys-Ala) specifically homes to fibrin-fibronectin complexes abundantly expressed in tumor microenvironment. In ...

CREKA Peptide in Nanotechnology and Drug Delivery

The integration of the CREKA peptide with nanocarriers has led to the development of advanced nanoplatforms作者：J Zhao·2015·被引用次数：117—A small nanoparticle drug delivery system was developed byconjugating fibrin-binding peptide CREKAto Polyamidoamine (PAMAM) dendrimer.. These CREKA peptide-based nanoplatforms offer enhanced targeting and drug delivery capabilities. For instance, conjugating fibrin-binding peptide CREKA to materials like dendrimers or carbon nanotubes creates sophisticated drug delivery systems. These peptide-conjugated nanoparticles are designed to specifically deliver therapeutic agents to diseased sites, minimizing off-target effects and improving treatment outcomes. The development of these recent advances of CREKA peptide-based nanoplatforms in biomedical applications highlights the peptide's growing importance.

Technical Aspects and Characterization

The CREKA peptide is often supplied as a trifluoroacetic acid salt, a trifluoroacetic acid form of a short peptide. Its purity and identity can be confirmed through analytical techniques such as High-Performance Liquid Chromatography (HPLC). For example, a UV chromatogram of CREKA peptide recorded at 220 nm can provide information about its purity and retention time, typically around 0.97 minutes for a high-purity sample2025年8月6日—CREKA(Cys-Arg-Glu-Lys-Ala), a pentapeptide that binds specifically to fibronectin (FN) [7] , has shown promise in tumor-targeted drug delivery .... Mass spectrometry can further confirm its molecular weight.

Future Directions and Considerations

While the CREKA peptide demonstrates significant potential, ongoing research continues to explore its full capabilities. Its role as a desirable targeting ligand is continually being validated across various disease models. As research progresses, the CREKA peptide is poised to play an increasingly vital role in the development of next-generation diagnostics and therapeutics, offering a more precise and effective approach to treating a range of complex diseases. The ongoing exploration of CREKA is a pentapeptide that has a high affinity to fibrin underscores its continued relevance in biomedical innovation.